Washington, DC — November 4, 2025 — Leads & Copy — DEA Administrator Terrance “Terry” Cole faces criticism for the agency’s contrasting approaches to combating illegal drug operations and hindering medical cannabis research.
While the DEA aggressively targets Chinese-backed illegal marijuana operations and fentanyl traffickers, its bureaucracy stalls federally compliant medical cannabis research programs, hindering potential treatments for diseases like Huntington’s and multiple sclerosis.
MMJ International Holdings President & CEO Duane Boise urges the DEA to separate crime from science, fast-track research programs, and collaborate with the FDA and HHS to build transparent supply chains for medical-grade cannabis materials. MMJ is represented by attorney Megan Sheehan.
Madison Hisey, MHisey@mmjih.com, 203-231-85832
Source: MMJ International Holdings
